Found 144 clinical trials
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding …
- 0 views
- 19 Feb, 2024
Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19
In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group.
- 0 views
- 19 Feb, 2024
Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19
Objectives : Primary objective: To describe the lung ultrasound lesions in pregnant women in case of suspected or confirmed COVID-19 Secondary objectives: To compare the lung ultrasound lesions with chest Computed Tomography -scanner (CT-Scan) lesions To evaluate the performances of the lung ultrasound to diagnose COVID-19 in pregnant women To …
- 0 views
- 19 Feb, 2024
Effect of Quercetin on Prophylaxis and Treatment of COVID-19
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. The investigators hypothesize that quercetin, as a strong scavenger and anti-inflammatory agent, can be effective on both prophylaxis and treatment of COVID-19 cases. Therefore, …
- 0 views
- 19 Feb, 2024
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.
- 0 views
- 19 Feb, 2024
Study of the Efficacy and Safety of Intravenous Pamrevlumab in Hospitalized Patients With Acute COVID-19 Disease
This is a Phase 2 trial to evaluate the efficacy and safety of intravenous (IV) infusions of pamrevlumab as compared to placebo in hospitalized subjects with acute COVID-19 disease.
- 0 views
- 19 Feb, 2024
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19
The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350 participants will be assigned to group that takes HCQ or group that opts to not take study medication. Participants will be UNM HEALTH SYSTEM HCW at high risk for occupational exposure to SARSCoV- 2. Study …
- 0 views
- 19 Feb, 2024
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in NAb levels in the recipient in hospitalized patients with COVID-19.
- 0 views
- 19 Feb, 2024
A Study to Evaluate the Efficacy Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy in Patients With Coronavirus Disease 19 (COVID-19)
At present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate further treatments such as ventilation, and can lower your virus number if given in addition to …
- 0 views
- 19 Feb, 2024
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19.
- 0 views
- 19 Feb, 2024